Picture of Prostatype Genomics AB logo

PROGEN Prostatype Genomics AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Brief: Prostatype Genomics Q3 EBITDA Stable At SEK 3.6 Mln

Nov 18 (Reuters) - Prostatype Genomics AB  PROGEN.ST :
    * Q3 NET SALES AMOUNTED TO 426 (556) TSEK
    * Q3 EBITDA AMOUNTED TO -3 613 (-3 555) TSEK
    * CURRENTLY STUDYING POSSIBILITIES OF COMBINING TWO MODERN
BIOMARKERS INTO WHAT CAN DEVELOP INTO A VERY INTERESTING
OPPORTUNITY

Source text for Eikon:  ID:nWkr7bKn65 
Further company coverage:  PROGEN.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))

Recent news on Prostatype Genomics AB

See all news